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ontrast Nephropathy:
eview Focusing on Prevention
icha Maeder, MD,* Maja Klein, MD,† Thomas Fehr, MD,‡ Hans Rickli, MD*
t. Gallen, Switzerland; and Boston, Massachusetts
Contrast nephropathy (CN) accounts for significant morbidity and mortality. Patients with
pre-existing renal insufficiency, especially those with diabetic nephropathy, are at particular
risk. Medullary hypoxia due to decreased renal blood flow and direct cytotoxicity contribute
to the pathogenesis. Contrast nephropathy is usually defined as an increase in serum
creatinine concentration0.5 mg/dl or 25% above the baseline level within 48 h. Intravenous
hydration (saline 0.45%, if tolerated 0.9% at a rate of 1 ml/kg/h) 12 h before and after contrast
exposure and the use of low or iso-osmolality contrast agents are advisable. The benefit of
low-dose dopamine as well as the selective dopamine-1 receptor agonist fenoldopam is
unproven. Studies on the effectiveness of the adenosine antagonist theophylline have led to
conflicting results. Because theophylline has a narrow therapeutic range and may be associated
with adverse effects, it is not a prophylactic agent of first choice. The administration of
N-acetylcysteine (NAC) has been evaluated in several trials with inconsistent results. Newer
data suggest a benefit of high-dose NAC (1,200 mg twice daily) for patients receiving high
doses (140 ml) of contrast agent, or those with advanced renal insufficiency (creatinine2.5
mg/dl). Whereas prophylactic hemodialysis does not prevent CN, a recent study demon-
strated a marked benefit of prophylactic hemofiltration. (J Am Coll Cardiol 2004;44:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.06.0751763–71) © 2004 by the American College of Cardiology Foundation
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(ontrast nephropathy (CN) is the third leading cause of
ospital-acquired acute renal failure accounting for 10% of all
ases (1) and contributing to prolonged hospital stay and
ncreased medical costs (1,2). Renal failure after contrast
dministration requiring in-hospital dialysis is associated with
oor outcome including 36% in-hospital mortality and 19%
wo-year survival (3,4). Patients with renal insufficiency carry
n inherent risk of developing atherosclerosis (5), and thus will
e frequently referred for angiography. On the other hand,
atients with cardiovascular disease often have concomitant
mpairment of renal function or receive medication associated
ith an increased risk of CN while undergoing angiography,
uch as angiotensin-converting enzyme inhibitors (ACEI).
herefore, even the most careful patient selection cannot avoid
hat a high number of patients at risk will be exposed to a
ontrast agent.
ISK FACTORS
he most important risk factor for CN is preexisting renal
ysfunction (2–4). The presence of diabetes mellitus has
ignificant impact on the incidence of CN in patients with
ild-to-moderate renal insufficiency (creatinine 2.0 mg/
l), whereas, in patients with advanced renal insufficiency
creatinine 2.0 mg/dl), the incidence of CN in patients
ith diabetic and nondiabetic nephropathy does not differ
From the *Division of Cardiology, Department of Internal Medicine, †Division of
eneral Internal Medicine, Department of Internal Medicine, Kantonsspital St.
allen, St. Gallen, Switzerland; and the ‡Transplantation Biology Research Center,
assachusetts General Hospital, Boston, Massachusetts.l
Manuscript received April 26, 2004; revised manuscript received May 30, 2004,
ccepted June 22, 2004.2). The degree of pre-existing renal impairment is the most
owerful predictor of CN, and patients with atherosclerosis
nd reduced effective circulating arterial volume are at
articular risk (Table 1). Peripheral vascular disease, bypass
raft intervention, and the need for an intra-aortic balloon
ump probably are surrogates of more severe atherosclerosis,
dvanced and long-lasting coronary artery disease. Proce-
ures with bypass angiography and intervention may be
ssociated with higher complexity, longer duration, and
imited success, thus indicating an unstable postprocedural
eriod with impaired cardiac output. In addition, older age,
ypertension, repeated exposure to contrast medium, and
ephrotoxic medication, such as aminoglycosides, as well as
rugs impairing the renovascular autoregulation such as
on-steroidal anti-inflammatory drugs (NSAID) and ACEI
ere reported to be risk factors (6).
Contrast nephropathy is rare in patients with normal
enal function in the absence of diabetes mellitus (2,7).
ihal et al. (2) found a 2% incidence of CN in nondiabetic
atients with a baseline creatinine 1.1 mg/dl. On the
ther hand, 50% of patients with diabetic nephropathy and
mean serum creatinine of 5.9 mg/dl had a 25% increase
fter coronary angiography (8).
ONTRAST AGENTS
ontrast agents are classified according to their osmolality,
hich depends on the ratio of iodine atoms to osmotically
ctive particles (Table 2). High osmolal contrast agents
about 2,000 mOsm/kg H2O) are considerably hyperosmo-
al compared with plasma. Diatrizoate is a tri-iodinated
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Contrast Nephropathy November 2, 2004:1763–71enzoate and thus a ratio 1.5 agent, because the substance
issociates into two osmotically active particles for each
hree iodine atoms. The so-called low osmolality contrast
gents have a lower osmolality (about 600 to 900 mOsm/kg
2O), but are still hyperosmolal to plasma. These sub-
tances are either nonionic monomers with three iodine
toms for each osmotically active particle or ionic dimers
ith six iodine atoms for each two osmotically active
articles, respectively (ratio 3 agents). Iodixanol is a non-
onic dimer with six iodine atoms for each osmotically active
article (ratio 6 agent) and iso-osmolal to plasma (9).
ATHOGENESIS
he pathogenesis of CN is not completely understood. Dis-
urbances in renal hemodynamics and direct cytotoxicity have
een identified as key factors (10). The renal medulla has an
xtremely low oxygen tension due to high transport activity of
he medullary thick ascending limb and, therefore, is especially
usceptible to ischemia (10). In animal models of renal insuf-
ciency, selective medullary injury after contrast administration
Abbreviations and Acronyms
ACEI  angiotensin-converting enzyme inhibitor
A2  adenosine-2-receptor
CN  contrast nephropathy
DA1  dopamine-1-receptor
NAC  N-acetylcysteine
NSAID  non-steroidal anti-inflammatory drug
Table 1. Independent Predictors for the Devel
Risk Factor
Contrast nephropathy†
Pre-existing renal failure
Preprocedural creatinine 2.0–2.9 mg/dl
Preprocedural creatinine 3 mg/dl
Diabetes
Creatinine 0–1.1 mg/dl
Creatinine 1.2–1.9 mg/dl
Creatinine 2.0–2.9 mg/dl
Creatinine 3.0
Preprocedure shock
Myocardial infarction 24 h
Congestive heart failure
Peripheral vascular disease
Contrast volume
Total contrast volume (per 100 ml)
Contrast nephropathy requiring dialysis
Chronic renal insufficiency‡
Diabetes
Contrast volume
Intra-aortic balloon pump
Bypass graft intervention
*Data are mainly derived from two studies (2,3) restricted to
only diagnostic angiography; †defined as increase in serum creatin
presence of previously documented renal insufficiency or a baselineas been shown, mediated by vasoconstrictors such as endo-
helin, vasopressin, and adenosine (10,11).
As renal function declines, a number of abnormalities
evelop including endothelial dysfunction, changes in co-
gulation and fibrinolysis, and advanced vascular and valvu-
ar calcification, all of which contribute to the acceleration of
ardiovascular disease (12). Worsening cardiac and vascular
unction, in turn, may lead to decreased cardiac output and
ubsequently reduced effective circulating arterial blood
olume and activation of the renin-angiotensin-aldosterone
ystem. Although antagonism of the renin-angiotensin-
ldosterone system has been proven to slow the long-term
rogression of the disease in patients with cardiorenal risk
13,14), in presence of acute contrast-induced reduction of
enal blood flow, blunting of the vasoconstrictor effects of
ngiotensin II on the efferent arteriola may be deleterious
ue to reduction of intra-glomerular pressure. The concom-
tant use of NSAIDs leading to withdrawal of the relaxing
ffects on the afferent arteriola by prostaglandins will further
educe glomerular filtration rate, thus precipitating acute
enal failure.
Furthermore, a direct toxic effect of contrast media on
enal epithelial cells has been shown (15), as well as an
ncreased red cell aggregation, possibly further impairing
xygen delivery (16). Experimental studies on the role of
smolality per se in the pathogenesis of CN have provided
onflicting data (16–18). Clinical trials indicate a lower
ncidence of CN when using low-osmolality compared with
igh-osmolality contrast agents (7,19), and when using
nt of Contrast Nephropathy
dds
tio
95% Confidence
Interval Reference*
.37 4.78–11.39 (2)
.82 8.01–20.54 (2)
.61 1.21–2.16 (2)
.86 1.20–2.89 (2)
.42 1.54–3.79 (2)
.00 0.48–2.08 (2)
.36 0.63–2.92 (2)
.19 0.72–1.96 (2)
.85 1.31–2.63 (2)
.53 1.21–2.10 (2)
.71 1.23–2.37 (2)
.12 1.02–1.23 (2)
.25 11.48–35.71 (3)
.34 1.92–5.81 (3)
.47 1.40–21.32 (4)
.10 1.0003–1.22 (3)
.008 1.002–1.013 (4)
.94 1.08–3.49 (3)
.94 1.16–20.9 (3)
ts undergoing percutaneous coronary interventions but notopme
O
Ra
7
12
1
1
2
1
1
1
1
1
1
1
20
3
5
1
1
1
4
patien
ine 0.5 mg/dl from preprocedural values; ‡defined as the
creatinine level of at least 1.8 mg/dl (159.1 mol/l).
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November 2, 2004:1763–71 Contrast Nephropathyso-osmolal rather than low-osmolality compounds (20). A
arge study comparing the low-osmolality agent iohexol to
he high-osmolality agent diatrizoate in patients with pre-
xisting renal dysfunction undergoing angiography found a
ower incidence of CN (defined as an increase in serum
reatinine 0.5 mg/dl within 48 to 72 h) in the iohexol
roup (12.2%) than in the diatrizoate group (27%). This
ffect was even more evident in patients with both renal
ysfunction and diabetes (7). The incidence of CN (defined
s an increase in serum creatinine 0.5 mg/dl within three
ays) in patients with both diabetes and pre-existing renal
ysfunction was recently reported to be markedly lower
hen using the iso-osmolal contrast agent iodixanol (3%)
ompared with iohexol (26%) (20).
EFINITION AND DIAGNOSIS
n clinical trials CN was defined as an increase in serum
reatinine 0.5 mg/dl (44 mol/l) (2,21–30) or 25% of
he baseline level (4,29,31–34) at 24 (30), 48 (2,21–34), or
arely 72 (33), 96 (34), or 120 (4) h after contrast exposure.
ecause creatinine peaks between four and five days after
ontrast administration (33,35), CN may escape in a con-
iderable number of patients relying on the creatinine
oncentration assessed only up to 48 h. Furthermore, serum
reatinine is an inaccurate estimate of creatinine clearance,
hich is better calculated according to the formula of
ockcroft and Gault (36) or the modification of diet in
enal disease (MDRD) study equation (37).
Cystatin C is a cationic non-glycosylated low-molecular-
eight cysteine protease that is produced by all nucleated
ells at a constant rate, is not metabolized in the serum, and
s freely filtered by the renal glomeruli (38,39). Serum
oncentration of cystatin C has been reported to be superior
o serum creatinine with regard to assessment of glomerular
ltration rate (38), and to be independent of age, gender,
nd muscle mass (39). A recent study provides evidence for
he usefulness of cystatin C as a marker of CN (39).
ystatin C levels peaked at 24 h after contrast administra-
ion and reached baseline levels within 48 h, whereas
Table 2. Classification of Contrast Agents Acc
Osmola
(mOsm/kg
High osmolal
Sodium-meglumine (Hypaque-76) 2,16
Diatriozate meglumine/sodium
(Renografin-76)
1,94
Low osmolal
Iohexol (Omnipaque) 84
Iopamidol (Isovue) 79
Iopromide (Ultravist) 77
Ioversol (Opitray) 70
Ioxaglate (Hexabrix) 60
Iso-osmolal
Iodixanol (Visipaque) 29
*Ratio of iodine atoms to osmotically active particles.reatinine levels continued to increase at 48 h. Unfortu- Hately, there are other factors than renal function influenc-
ng cystatin C levels (e.g., malignant tumors [40] or eleva-
ion of C-reactive protein [41]).
Acute worsening of renal function after angiography in
atients with atherosclerosis may be due to cholesterol
mbolization rather than CN in certain cases. Concomitant
kin lesions will indicate cholesterol embolization, whereas
n other cases it will be very hard to distinguish between the
wo entities. Eosinophilia and preprocedural elevation of
-reactive protein enhances the probability of microemboli
42,43).
OLE OF PROPHYLACTIC INTERVENTIONS
ydration. Relying on the observation of a higher inci-
ence of CN in dehydrated patients and the beneficial effect
f hydration compared with vasodilators and mannitol as
djuncts to hydration (44), the periprocedural administra-
ion of fluids has become standard. In most studies, a
niform protocol with half-isotonic (0.45%) saline at a rate
f 1 ml/kg/h before and after contrast exposure was em-
loyed (23–30). One study compared the administration of
sotonic to half-isotonic saline in 1,383 patients undergoing
oronary angiography (21). Contrast nephropathy occurred
n 0.7% of the patients assigned to 0.9% saline, and in 2.0%
f those assigned to half-isotonic saline (p  0.04). Three
ubgroups demonstrated particular benefit: women, diabet-
cs, and those receiving high volumes of contrast (250 ml).
ecause only 20% of the study population had pre-existing
enal insufficiency, conclusions about the optimal hydration
rotocol in high-risk patients are limited. In this study
ntravenous fluids were initiated only a few hours before
ngiography, relying on the data of a small trial showing
on-inferiority of a combination of oral and intravenous
re-catheterization hydration (1,000 ml clear liquid over
0 h followed by saline 0.45% 300 ml/h over 6 h) compared
ith overnight intravenous hydration (saline 0.45% 75
l/h) in patients with mild-to-moderate renal dysfunction
ndergoing angiography (postcatheterization hydration
ith saline 0.45% 75 ml/h over 12 h for all patients) (45).
g to Their Osmolality (9)
) Ionic/Nonionic Ratio*
Viscosity
(mPa  s)
Ionic 1.5 (3:2) 13.3
Ionic 1.5 (3:2) 10
Nonionic 3 (3:1) 20.4
Nonionic 3 (3:1) 20.7
Nonionic 3 (3:1) 10.0
Nonionic 3 (3:1) 9.9
Ionic 3 (6:2) 15.7
Nonionic 6 (6:1) 26ordin
lity
H2O
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Contrast Nephropathy November 2, 2004:1763–71ut additional intravenous administration seems to be infe-
ior to intravenous hydration (46).
Based on the hypothesis that alkalizing renal tubular fluid
ith bicarbonate may reduce free radical formation and thus
educe injury, a prospective, single-center trial evaluated an
lternative hydration protocol with sodium bicarbonate
47). Patients with pre-existing renal insufficiency scheduled
or different procedures (mainly cardiac catheterization)
ere randomized to receive either 154 mEq/l sodium
icarbonate (n  60; creatinine 1.89  0.69 mg/dl) or
quiosmolar sodium chloride (n  59; creatinine 1.71 
.42 mg/dl), both given as an intravenous bolus (3 ml/kg/h
or 1 h) immediately before administration of iopamidol,
ollowed by an infusion at a rate of 1 ml/kg/h for 6 h after
he procedure. The incidence of CN (defined as an increase
f 25% of baseline creatinine within two days) was
arkedly lower in the bicarbonate group (1.7%) than in the
odium chloride group (13.6%; p  0.02). These very
romising results are hampered only by the fact that a 7-h
nstead of a 24-h hydration period was used, which does not
llow direct comparison with previous studies. Therefore,
urther studies are required to clarify the role of sodium
icarbonate hydration in the prevention of CN.
iuretics. Relying on the idea that inducing and maintain-
ng a post-contrast diuresis and blocking of the oxygen-
emanding active transport processes of the medullary thick
scending limb would prevent CN, furosemide was given as
rophylaxis. However, the landmark trial of Solomon et al.
22) rejected the hypothesis that the administration of
urosemide or mannitol plus hydration would more effi-
iently prevent CN than hydration alone. The failure of
urosemide can probably be explained by loop diuretic-
nduced hypovolemia. In current practice diuretics usually
re withdrawn before contrast exposure whenever possible.
opamine and fenoldopam. Dopamine at “low dose” (5
g/kg/min) stimulates dopamine and possibly beta-receptors,
hereby increasing renal blood flow and glomerular filtration
48). However, studies comparing saline plus low-dose dopa-
ine to hydration alone disclosed negative (49) or neutral (48)
ffects. Abizaid et al. (49) studied 60 patients (creatinine1.5
g/dl) undergoing coronary angiography randomized to saline
0.45% 1 ml/kg/h for 12 h before and after the procedure)
lone, or dopamine (2.5 g/kg/min) plus saline, or amino-
hylline (4 mg/kg followed by a drip of 0.4 mg/kg/h) plus
aline. There was a non-significant trend toward a higher
ncidence of CN in patients receiving dopamine. The failure of
opamine may be, at least in part, due to hypovolemia and
achyarrhythmia induced by diuretic, potassium-wasting, and
ro-arrhythmogenic effects, both leading to reduced cardiac
utput and reduced effective circulating arterial volume,
hereby blunting the positive inotropic properties of dopamine.
he adverse effect of dopamine was further explained by
nselective stimulation of both dopamine-1 and -2 receptors
48). In contrast, dopamine-1 stimulation with the selective
opamine-1 agonist fenoldopam was shown to prevent the
iatrizoate-induced reductions in the glomerular filtration rate wn anesthetized volume-depleted dogs (50). The promising
esults of a prospective pilot study (51) evaluating fenoldopam
s an adjunct to hydration were not confirmed. In contrast, a
ecent multicenter study (52) comparing fenoldopam plus
ntravenous hydration to placebo plus hydration in patients
ith a creatinine clearance 60 ml/min undergoing coronary
ngiography demonstrated a trend in favor of placebo (CN in
0.1% of patients assigned to placebo vs. 33.6% of the
enoldopam group; p  NS).
asodilators. In a canine model of renal insufficiency
subtotal nephrectomy), adenosine was shown to act as a
asoconstrictor after iohexol administration, whereas vaso-
ilation was induced in sham-operated dogs (11). These
ifferences were explained by contrast-induced adenosine-
-receptor-mediated vasodilation in dogs with normal func-
ion, and conversely both early adenosine-2-receptor-
ediated vasodilation and sustained and overwhelming
denosine-1-receptor-mediated vasoconstriction in dogs
ith impaired renal function. Two studies evaluating the
ffect of the adenosine antagonist theophylline either as a
ingle intravenous bolus of 200 mg (53) or as oral intake of
00 mg twice a day starting 24 h before and continuing 48 h
fter coronary angiography in addition to saline hydratation
54) were promising. A contradictory study found no benefit
f the oral administration of 810 mg theophylline during
ve days and (not uniform) hydration compared with
ydration alone in patients with chronic renal insufficiency
ndergoing either computed tomography or digital sub-
traction angiography (55).
In a recently published trial (6), 100 patients were randomly
ssigned to receive either placebo (creatinine 1.72  0.69
g/dl) or theophylline 200 mg intravenously (creatinine 1.65
0.41 mg/dl) 30 min before coronary angiography resulting
n a significantly lower incidence of CN in the theophylline
roup (4% vs. 20% in the saline group; p  0.0138). Unfor-
unately, hydration was not uniform, but patients were given
uids “according to clinical examination, X-ray, and central
enous pressure” (6). Because data are conflicting and theoph-
lline has a narrow therapeutic range and may be associated
ith adverse effects (e.g., tachycardia), it is not a prophylactic
gent of first choice.
Among theoretically possible candidates to prevent CN,
either atrial natriuretic peptide (56), nor a mixed endothe-
in antagonist (57), nor dihydropyridine calcium channel
lockers (58) led to favorable results in clinical studies.
-acetylcysteine (NAC). Relying on the assumption that
eactive oxygen species might be involved in the pathogen-
sis of CN, Tepel et al. (59) compared the oral administra-
ion of the antioxidant NAC (600 mg twice a day on the day
efore and day of examination) plus standard hydration to
ydration alone in 83 patients (creatinine 2.4  1.3 mg/dl)
ndergoing computed tomography with intravenous admin-
stration of 75 ml of nonionic, low-osmolality contrast
gent. The authors were able to demonstrate a significantly
ower incidence of CN in the NAC group (2%) compared
ith the placebo group (21%; p 0.01). However, this trial
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November 2, 2004:1763–71 Contrast Nephropathys hampered by the fact that the incidence of CN in the
ontrol group was much higher compared with the control
roup in the trial of Solomon et al. (22), although the
atients in the latter study underwent angiography instead
f computed tomography; received higher doses; and 32% of
atients received high-osmolality contrast agents compared
ith nonionic, low-osmolality contrast agents received by all
atients in the study by Tepel et al. (59).
Several trials designed to confirm the benefit of NAC in
atients with chronic renal insufficiency undergoing angiog-
able 3. Summary of Prospective Trials Published as Full-Text A
ydratation to Hydration for the Prevention of Contrast Nephro
Study
Patients
(n)
Baseline Serum
Creatinine
(mg/dl)†‡ NAC Reg
rospective trials showing no beneficial effect of NAC prophylaxis
Durham et al.* 79 NAC: 2.2  0.4
Placebo: 2.3  0.5
1,200 mg 1 h p
1,200 mg thr
the procedure
Boccalandro et al.* 179 NAC: 1.8  0.6
Placebo: 1.9  0.6
600 mg b.i.d. fo
doses starting
prior to proce
Allaqaband et al.* 85 NAC: 2.2  1.0
Placebo: 2.0  0.8
600 mg b.i.d. fo
doses starting
prior to proce
Goldenberg et al.* 80 NAC: 2.0  0.4
Placebo: 1.9  0.3
600 mg t.i.d. fo
doses starting
prior to proce
Briguori et al.* 183 NAC: 1.5  0.4
Placebo: 1.5  0.4
600 mg b.i.d. fo
doses starting
prior to proce
Oldenmeyer et al. 96 NAC: 1.6  0.8
Placebo: 1.7  0.7
1,500 mg b.i.d.
doses starting
evening befor
procedure
rospective trials demonstrating a favorable effect of NAC prophylaxis
Shyu et al.* 121 NAC: 2.8  0.8
Placebo: 2.8  0.8
400 mg b.i.d. fo
doses starting
prior to the p
Diaz-Sandoval et al.* 54 NAC: 1.7  0.1
Placebo: 1.6  0.1
600 mg b.i.d. on
before, and th
after the proc
Kay et al.* 200 NAC: 1.3 (0.8–3.7)
Placebo: 1.2 (0.8–3.0)
600 mg b.i.d. fo
doses starting
prior to proce
MacNeill et al. 43 NAC: 1.9  0.4
Placebo: 1.9  0.4
600 mg, two do
three doses af
procedure
Baker et al. 80 NAC: 1.9  0.6
Placebo: 1.8  0.4
150 mg/kg in 5
saline 0.9% IV
min immedia
before the pro
followed by 5
in 500 ml sal
for 4 h
Study included in the meta-analysis by Goldenberg et al. (26); †mean values  SD o
alues by 88.4; §a uniform hydration protocol was used, saline 0.45% at a rate of 1 m
or 12 h before and after the procedure (24), or saline 0.9% 1 ml/kg/h for 12 h befo
0.5 mg/dl above baseline level 48 h after contrast exposure; ¶defined as increase in
defined as increase in serum creatinine concentration25% above the baseline level 2
25% above the baseline level 48 or 96 h after contrast exposure.
b.i.d.  twice a day; CN  contrast nephropathy; IV  intravenously; NAC aphy provided conflicting results (23–34). There were tarked differences concerning grade of renal insufficiency of
ncluded patients, NAC regime, and type and amount of
ontrast agent administered, as shown in Table 3. The
uthors of a recent meta-analysis excluding several studies
or various reasons (e.g., intravenous NAC administration)
ound a benefit of NAC prophylaxis and recommended it
or high-risk patients (60), whereas the authors of two other
eta-analyses released in 2004 (61,62) stated that general
onclusions about a benefit of NAC to prevent CN are
mpossible due to inconsistent study design in the analyzed
es Until March 2004 Comparing N-Acetylcysteine Plus
in Patients Undergoing Angiography (23–27,29–34)
Uniform
Hydratation
Protocol
Employed§
Contrast
Agent
Amount of
Contrast Agent
(ml) CN Incidence
d
fter
Yes Iohexol NAC: 77.4  35.9
Placebo: 84.7  42.1
NAC: 26.3%
Placebo: 22.0%
p  NS
Yes Iodixanol NAC: 192  142
Placebo: 191  120
NAC: 13%
Placebo: 12%
p  NS
Yes Ioversol NAC: 122  65
Placebo: 122  75
NAC: 17.7%
Placebo: 15.3%
p  NS
Yes Iopamidol NAC: 111  43
Placebo: 121  49
NAC: 10%
Placebo: 8%
p  NS
Yes Iopromide NAC: 194  127
Placebo: 200  144
NAC: 6.5%#
Placebo: 11%#
p  NS
ur Yes Iopamidol NAC: 134  71
Placebo: 127  73
NAC: 8.2%#
Placebo: 6.4%#
p  NS
ure
Yes Iopamidol NAC: 119  3
Placebo: 115  48
NAC: 3.3%
Placebo: 24.6%
p  0.001
e
oses
No Ioxilan NAC: 179  8
Placebo: 189  12
NAC: 8%¶
Placebo: 45%¶
p  0.005
Yes Iopamidol NAC: 120 (70–380)
Placebo: 130 (75–320)
NAC: 4%¶
Placebo: 12%¶
p  0.03
ior,
e
No Iopromide
or ioxilan
NAC: 103  52
Placebo: 116  63
NAC: 5%#
Placebo: 32%#
p  0.046
30
e,
kg
%
No Iodixanol NAC: 238  165
Placebo: 222  162
NAC: 5%**
Placebo: 21%**
p  0.045
an (interquartile range); ‡to convert from mg/dl to mol/l, multiply serum creatinine
12 h before and 12 h after the procedure (23,25–27,29,32), saline 0.45% at 75 ml/h
6 h after the procedure (31); defined as increase in serum creatinine concentration
creatinine concentration 25% above the baseline level 48 h after contrast exposure;
or 72 h after contrast exposure; **defined as increase in serum creatinine concentration
tylcysteine; NS  not significant; t.i.d.  three times a day.rticl
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Contrast Nephropathy November 2, 2004:1763–71In one of the most recent trials on the subject, 80 patients
creatinine clearance 50 ml/min) undergoing coronary
ngiography with iopamidol were randomized to receive
ither NAC 600 mg three times a day for 48 h starting 24 h
efore contrast administration plus hydration (0.45% saline
t 1 ml/kg/h for 12 h before and after contrast exposure) or
lacebo plus hydration (26). The incidence of CN did not
iffer between the NAC group (10%) and the placebo group
8%; p  0.52).
A meta-analysis of eight prospective studies comprising
,023 patients (23–27,29–31) in the same paper (26) found an
verall benefit of NAC (odds ratio 0.53 [95% confidence
nterval 0.35 to 0.78]). However, the authors pointed out that
wo of the three studies favoring NAC administration were
sing a nonuniform or incomplete hydration protocol as well as
lightly different definitions of CN (25% instead of 0.5 mg/dl
ncrease above baseline creatinine), and they, therefore, con-
luded that NAC administered as adjunct to a uniform 24-h
ydration protocol provides no additional benefit.
Although the available data do not allow conclusions about
he usefulness of NAC in general, some of these trials dealing
ith subgroups of patients provide interesting results. Of
pecial importance is the study by Shyu et al. (27), which
ompared NAC plus hydration to hydration alone in patients
ith the highest ever NAC trial-tested creatinine levels (2.8
.8 mg/dl) and found a markedly lower incidence of CN in the
AC group (3.3%) than in the hydration group (24.6%; p 
001). Baker et al. (34) for the first time evaluated the
ntravenous administration of NAC combined with a short-
ned hydration protocol (Table 3) resulting in a significantly
ower incidence of CN in the NAC group (5%) than in the
aline group (21%; p 0.045). Briguori et al. (28) compared a
tandard NAC dose (SD group, 600 mg twice a day) to a
ouble NAC dose (DD group, 1,200 mg twice a day) in
ddition to intravenous saline 0.45% (1 ml/kg/h) for 12 h
efore and after coronary or peripheral angiography in patients
ith chronic renal insufficiency (creatinine1.5 mg/dl and/or
reatinine clearance 60 ml/min). Contrast nephropathy oc-
urred in 11% of patients in the SD group and in 3.5% of
atients in the DD group (p  0.038). In the subgroup with
he contrast dose 140 ml, CN was more frequent in the SD
roup (18.9%) than in the DD group (5.4%; p  0.039),
hereas no difference was found in the low-dose (140 ml)
ubgroup.
emodialysis and hemofiltration. The hypothesis that he-
odialysis might prevent CN by removing contrast media
rom the circulation was not confirmed in clinical trials (63,35).
he largest study on this subject included 113 patients with
dvanced renal insufficiency (creatinine 3.5  1.2 mg/dl)
ndergoing different procedures with administration of non-
onic, low-osmolality contrast agent (35). Patients were given
ither periprocedural hydration (saline at 1 ml/kg/h for 12 h
efore and after contrast exposure) or preprocedural hydration
saline at 1 ml/kg/h for 12 h) followed by a 3-h hemodialysis.
ine patients in the non-hemodialysis group and 13 in theemodialysis group (p  NS) developed CN (maximum mncrease in creatinine 1.5 mg/dl or 50% above baseline).
here was no benefit of hemodialysis in the subgroup receiving
150 ml of contrast agent.
Marenzi et al. (64) studied 114 patients (creatinine 2
g/dl) undergoing coronary angiography with nonionic, low-
smolality contrast agent, who were randomly assigned to
ither venovenous hemofiltration in an intensive care unit
tarting 4 to 6 h before the coronary procedure and continuing
or 18 to 24 h (hemofiltration group, creatinine clearance 26
ml/min) or infusion of isotonic saline at a rate of 1 ml/kg/h
or 6 to 8 h before and 24 h after the procedure (control group,
reatinine clearance 26  8 ml/min). Three patients in the
emofiltration group (5%) developed CN compared with 28
atients in the control group (50%; p  0.001). In 10 control
atients, emergency hemodialysis was required, but in no
atient of the hemofiltration group. In-hospital mortality was
ignificantly lower in the hemofiltration group (2% vs. 14%; p
0.02). These impressive results were questioned due to the
ollowing reasons: the exceptionally high mortality of the
ontrol group and the fact that heparin administration and
ntensive care might have considerably added to the mortality
ifference. Furthermore, incorporation of this study into clin-
cal practice will raise important logistical issues.
ONCLUSIONS AND
HERAPEUTIC RECOMMENDATIONS
ll patients undergoing angiography should receive hydration.
uidelines (65) recommend at least 100 ml oral intake or
ntravenous administration per hour starting 4 h before to 24 h
fter contrast exposure. We suggest the use of an intravenous
ydration regime (saline 0.45%, at least 1 ml/kg/h 12 h before
nd after contrast exposure, if tolerated 0.9% saline) for all
atients with impaired renal function. Alternatively, a combi-
ation of oral and intravenous preprocedural hydration fol-
owed by postprocedural intravenous hydration according to
he protocol of Taylor et al. (45) can be used. However, this
egime might be unsuitable for patients with congestive heart
ailure. If the hydration period has to be shortened for any
eason, the use of sodium bicarbonate instead of sodium
hloride has to be considered. Diuretics, ACEIs, angiotensin
eceptor blockers, NSAIDs, and other nephrotoxic drugs
hould be withdrawn at least 24 h before contrast exposure. We
iscourage using dopamine, fenoldopam, and theophylline.
he smallest possible amount of a nonionic, low-osmolal or
so-osmolal contrast agent should be given, and repeated
ontrast administration within a short period of time should be
voided. Concerning the use of NAC, we agree with experts
66) who recently suggested that in patients with high creati-
ine levels (2.5 mg/dl) and in those receiving large contrast
oses (140 ml), high-dose NAC (2  1,200 mg) should be
iven. Because the contrast dose in complex coronary inter-
entions may easily exceed 140 ml, and because NAC is
nexpensive and has virtually no side effects, we suggest that all
atients with chronic renal insufficiency (creatinine 1.5
g/dl or creatinine clearance 60 ml/min) and all diabetics
s
s
N
s
t
a
F
r
m ice a d
1769JACC Vol. 44, No. 9, 2004 Maeder et al.
November 2, 2004:1763–71 Contrast Nephropathyhould receive high-dose NAC. Further large prospective
tudies are warranted to clarify the debate about the benefit of
AC in all other patients.
igure 1. Suggested algorithm for therapeutic recommendations to prevent
eceptor blocking agents, non-steroidal anti-inflammatory drugs, diuretics
ultiple myeloma, congestive heart failure, or age 70 years. b.i.d.  twA possible algorithm to choose the optimal prophylactic ttrategy in an individual patient is given in Figure 1. It has
o be emphasized that there are no studies about the best
pproach in patients undergoing emergency procedures. In
rast nephropathy. *Angiotensin-converting enzyme inhibitors, angiotensin
oglycosides, calcineurin inhibitors; †chronic renal insufficiency, diabetes,
ay; IV  intravenous.cont
, aminhese patients it will not be possible to start preventive
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Contrast Nephropathy November 2, 2004:1763–71easures including drug withdrawal, hydration, and NAC
ntake 12 to 24 h before contrast exposure. We suggest
eginning as soon as possible and adequately lengthening
he postcontrast period (e.g., for hydration: start immedi-
tely before angiography, duration until 24 h after angiog-
aphy). However, these suggestions are not evidence-based
nd await confirmation in future clinical trials.
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